key: cord-1008642-nubd2mok
authors: Blaszczak, Alecia; Trinidad, John C.L.; Cartron, Alexander M.
title: Adalimumab for Treatment of Hidradenitis Suppurativa During the COVID-19 Pandemic: Safety Considerations
date: 2020-04-10
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.04.030
sha: f6a31babe2266140d3f2b86a8736991be7c75dbf
doc_id: 1008642
cord_uid: nubd2mok

nan

highlights the risk of total infections, upper respiratory tract infections, and 48 pharyngitis in patients with HS on adalimumab versus placebo, from the data published in the 49 PIONEER I and II trials. 3 In patients with HS taking adalimumab, there is a modest increased risk 50 of total infections and nasopharyngitis by 2.5%, on average, with no difference in the risk of 51 upper respiratory tract infections. These results demonstrate that, in general, there was 52 minimal difference between rates of respiratory infections in HS patients on adalimumab versus 53

Much like data regarding the effect of immunosuppressive drugs on patients with 55 psoriasis, it is difficult to extrapolate data from the PIONEER I and II trials to susceptibility to 56 

Nonetheless, these data may be used by dermatologists to make 57 informed treatment decisions for patients with HS during the ongoing COVID-19 pandemic

Should biologics for psoriasis be interrupted in 80 the era of COVID-19?

Two 83 Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa